A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

NCT05789082 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

320

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Divarasib
DRUG: Pembrolizumab
DRUG: Carboplatin
DRUG: Cisplatin
DRUG: Pemetrexed

Sponsor

Hoffmann-La Roche